润都股份: 关于硫酸氨基葡萄糖氯化钠复盐获得化学原料药上市申请批准通知书的公告

Core Viewpoint - Zhuhai Runduo Pharmaceutical Co., Ltd. has received approval for the listing application of Glucosamine Sulfate Sodium Chloride Compound, which is expected to enhance the company's product portfolio and market competitiveness [1][2]. Group 1: Drug Approval Details - The drug name is Glucosamine Sulfate Sodium Chloride Compound, and the application was submitted by Zhuhai Runduo Pharmaceutical Co., Ltd. [1] - The approval notice was issued by the National Medical Products Administration, confirming that the drug meets the registration requirements [1]. - The application was accepted under the registration number Y20230001261, with the approval notice numbered 2025YS00693 [1]. Group 2: Impact on the Company - The approval of this drug is expected to positively impact the company's future operating performance by enriching its product categories [2]. - The drug is indicated for the treatment of primary and secondary osteoarthritis, which may enhance the company's market position [2].